The Financial Times has consulted the experts in drug discovery and settled on three new technologies that promise to transform patient care in years to come. Most FierceBiotech readers are already familiar with RNAi [1], where a number of companies are competing to advance new therapies. GWAS is second on the list; individual genetic variations that highlight a person's risk of disease. Finally the FT lists IPSCs, the pluripotent stem cells that act like embryonic stem cells. Big challenges have yet to be met in the field, but the experts say the long-term potential here is amazing.
- read the article [2] in the Financial Times
Related Articles:
More jaw-dropping scientific advances lay ahead [3]
Shares slip as developers see RNAi doubts [4]
Links:
[1] http://www.fiercebiotech.com/story/a-billion-dollar-lesson-in-rnai-economics/2007-07-09
[2] http://www.ft.com/cms/s/0/668c7654-4898-11dd-a851-000077b07658.html
[3] http://www.fiercebiotech.com/story/more-jaw-dropping-scientific-advances-lay-ahead/2008-01-02
[4] http://www.fiercebiotech.com/story/shares-slip-as-developers-see-rnai-doubts/2008-04-02